
Sign up to save your podcasts
Or
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
4.3
2323 ratings
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
13 Listeners
315 Listeners
107 Listeners
171 Listeners
868 Listeners
497 Listeners
688 Listeners
18 Listeners
278 Listeners
258 Listeners
3,323 Listeners
135 Listeners
1,103 Listeners
8,005 Listeners
195 Listeners
61 Listeners
8 Listeners
427 Listeners
313 Listeners